A study led by researchers at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health found that a single dose of the typhoid conjugate vaccine, Typbar TCV®, provides lasting efficacy in preventing typhoid fever in children aged 9 months to 12 years old. Published in The Lancet, the phase 3 clinical study enrolled over 28,000 healthy children in Malawi, with half receiving the TCV and the other half a meningococcal capsular group A conjugate (MenA) control vaccine. Over more than four years of follow-up, 24 children in the TCV group and 110 in the MenA group developed typhoid fever, resulting in an efficacy of 78.3 percent in the TCV group. The vaccine was effective in all age groups, and its efficacy remained strong throughout the study period, with only a slight decrease of 1.3 percent per year.
